Literature DB >> 34333739

Improvement in depressive symptoms after antiretroviral therapy initiation in people with HIV in Rakai, Uganda.

Noeline Nakasujja1, Alyssa C Vecchio2, Deanna Saylor3, Sarah Lofgren4, Gertrude Nakigozi5, David R Boulware, Alice Kisakye5, James Batte5, Richard Mayanja5, Aggrey Anok5, Steven J Reynolds6,7, Thomas C Quinn6,7, Carlos A Pardo3, Anupama Kumar5, Ronald H Gray8, Maria J Wawer8, Ned Sacktor3, Leah H Rubin9,10,11.   

Abstract

Depression is common following HIV infection and often improves after ART initiation. We aimed to identify distinct dimensions of depression that change following ART initiation in persons with HIV (PWH) with minimal comorbidities (e.g., illicit substance use) and no psychiatric medication use. We expected that dimensional changes in improvements in depression would differ across PWH. In an observational cohort in Rakai, Uganda, 312 PWH (51% male; mean age = 35.6 years) completed the Center for Epidemiologic Studies-Depression (CES-D) scale before and up to 2 years after ART initiation. Twenty-two percent were depressed (CES-D scores ≥ 16) pre-ART that decreased to 8% after ART. All CES-D items were used in a latent class analysis to identify subgroups with similar change phenotypes. Two improvement phenotypes were identified: affective-symptom improvement (n = 58, 19%) and mixed-symptom improvement (effort, appetite, irritability; n = 41, 13%). The affect-improvement subgroup improved on the greatest proportion of symptoms (76%). A third subgroup was classified as no-symptom changes (n = 213, 68%) as they showed no difference is symptom manifestation from baseline (93% did not meet depression criteria) to post-ART. Factors associated with subgroup membership in the adjusted regression analysis included pre-ART self-reported functional capacity, CD4 count, underweight BMI, hypertension, female sex(P's < 0.05). In a subset of PWH with CSF, subgroup differences were seen on Aβ-42, IL-13, and IL-12. Findings support that depression generally improves following ART initiation; however, when improvement is seen the patterns of symptom improvement differ across PWH. Further exploration of this heterogeneity and its biological underpinning is needed to evaluate potential therapeutic implications of these differences.
© 2021. Journal of NeuroVirology, Inc.

Entities:  

Keywords:  Antiretroviral; Depression; Global health; HIV; Heterogeneity

Mesh:

Substances:

Year:  2021        PMID: 34333739      PMCID: PMC8524346          DOI: 10.1007/s13365-020-00920-6

Source DB:  PubMed          Journal:  J Neurovirol        ISSN: 1355-0284            Impact factor:   3.739


  51 in total

1.  What can mental health interventions contribute to the global struggle against HIV/AIDS?

Authors:  Francine Cournos; Karen McKinnon; Milton Wainberg
Journal:  World Psychiatry       Date:  2005-10       Impact factor: 49.548

Review 2.  Analysis of neuropsychiatric adverse events during clinical trials of efavirenz in antiretroviral-naive patients: a systematic review.

Authors:  Brian Gazzard; Andrew Balkin; Andrew Hill
Journal:  AIDS Rev       Date:  2010 Apr-Jun       Impact factor: 2.500

3.  Accuracy of Biomarker Testing for Neuropathologically Defined Alzheimer Disease in Older Adults With Dementia.

Authors:  Howard A Fink; Eric J Linskens; Pombie C Silverman; J Riley McCarten; Laura S Hemmy; Jeannine M Ouellette; Nancy L Greer; Timothy J Wilt; Mary Butler
Journal:  Ann Intern Med       Date:  2020-04-28       Impact factor: 25.391

4.  Psychiatric issues in the management of patients with HIV infection.

Authors:  G J Treisman; A F Angelino; H E Hutton
Journal:  JAMA       Date:  2001-12-12       Impact factor: 56.272

5.  Efavirenz is related to neuropsychiatric symptoms among adults, but not among adolescents living with human immunodeficiency virus in Kilimanjaro, Tanzania.

Authors:  Marion Sumari-de Boer; Arnt Schellekens; Ashanti Duinmaijer; Julieth M Lalashowi; Happiness J Swai; Quirijn de Mast; Andre van der Ven; Grace Kinabo
Journal:  Trop Med Int Health       Date:  2017-12-20       Impact factor: 2.622

6.  The role of IL-12 and TGF-beta1 in the pathophysiology of major depressive disorder.

Authors:  Kyung-Min Lee; Yong-Ku Kim
Journal:  Int Immunopharmacol       Date:  2006-04-27       Impact factor: 4.932

7.  Longitudinal characterization of depression and mood states beginning in primary HIV infection.

Authors:  Jessica A Gold; Marie Grill; Julia Peterson; Christopher Pilcher; Evelyn Lee; Frederick M Hecht; Dietmar Fuchs; Constantin T Yiannoutsos; Richard W Price; Kevin Robertson; Serena Spudich
Journal:  AIDS Behav       Date:  2014-06

8.  Prediction of neuropsychiatric adverse events associated with long-term efavirenz therapy, using plasma drug level monitoring.

Authors:  Félix Gutiérrez; Andrés Navarro; Sergio Padilla; Rosa Antón; Mar Masiá; Joaquín Borrás; Alberto Martín-Hidalgo
Journal:  Clin Infect Dis       Date:  2005-10-19       Impact factor: 9.079

9.  Heterogeneity in neurocognitive change trajectories among people with HIV starting antiretroviral therapy in Rakai, Uganda.

Authors:  Leah H Rubin; Deanna Saylor; Gertrude Nakigozi; Noeline Nakasujja; Kevin Robertson; Alice Kisakye; James Batte; Richard Mayanja; Aggrey Anok; Sarah M Lofgren; David R Boulware; Raha Dastgheyb; Steven J Reynolds; Thomas C Quinn; Ronald H Gray; Maria J Wawer; Ned Sacktor
Journal:  J Neurovirol       Date:  2019-06-19       Impact factor: 2.643

10.  Depression symptoms and cognitive function among individuals with advanced HIV infection initiating HAART in Uganda.

Authors:  Noeline Nakasujja; Richard L Skolasky; Seggane Musisi; Peter Allebeck; Kevin Robertson; Allan Ronald; Elly Katabira; David B Clifford; Ned Sacktor
Journal:  BMC Psychiatry       Date:  2010-06-10       Impact factor: 3.630

View more
  1 in total

1.  Optimizing PMTCT Adherence by Treating Depression in Perinatal Women with HIV in South Africa: A Pilot Randomized Controlled Trial.

Authors:  Christina Psaros; Amelia M Stanton; Greer A Raggio; Nzwakie Mosery; Georgia R Goodman; Elsa S Briggs; Marcel Williams; David Bangsberg; Jenni Smit; Steven A Safren
Journal:  Int J Behav Med       Date:  2022-03-08
  1 in total

北京卡尤迪生物科技股份有限公司 © 2022-2023.